secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viracta Therapeutics, Inc. (—)
CIK:        0001061027
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0000950170-25-014630
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viracta Therapeutics terminates employees, wind down operations; all directors resign
--------------------------------------------------------------------------------

- Board approved workforce reduction effective Feb 5, 2025; expects ~$0.1M in severance and related costs.
- All directors (Pomerantz, Borellini, Darcy, Royston, Rothera) resigned; CEO Rothera, CFO Faerm, CMO Cohen cease officer roles.
- Craig Jalbert appointed sole director, CEO, President, CFO, Treasurer and Corporate Secretary; compensated $50K/yr for 3 years.
- Company exploring strategic alternatives for its virus-associated cancer development programs.
- Wind down follows clinical-stage operations; stock ticker VIRX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/virx-20250203.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-014630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer